Insulet Corporation reports Q2 results on August 6 with a street that has spent the past month trimming targets yet holding its ratings — a setup where conviction remains intact but patience is being tested.
The most telling signal this week comes from options. Investors are leaning unusually bullish into the print, with the put/call ratio at 0.309 — well below its 20-day average of 0.359 and close to its 52-week low of 0.294. That gap represents roughly 1.4 standard deviations of net call-side dominance, a level last seen only briefly across the past year. Options traders are not hedging this one; they are positioned for upside. That stands in contrast to the stock's subdued price action, which is flat on the week at $166.82 and has recovered only modestly from what earlier notes flagged as a roughly 41% YTD drawdown.
Short positioning is a secondary angle, not the lead. Short interest is running at 6.5% of free float — meaningful but not extreme — and edged up about 2.3% over the week after falling sharply through most of July, down 12% across the past month. The borrow market is loose by any measure: shares available to borrow represent nearly 4,000% of current short interest, and borrowing costs are negligible at under 0.5%. There is no squeeze pressure here. The week-on-week uptick in short interest looks more like modest repositioning ahead of earnings than a fresh conviction short. The ORTEX short score of 41.6 sits comfortably in neutral territory and has drifted slightly lower over the past two weeks from a local high near 44.
Analyst sentiment tells a nuanced story. The direction of travel on price targets has been consistently downward over the past month — Stifel cut to $225 from $250, RBC trimmed to $245 from $280, and Truist lowered to $210 from $219, all while maintaining positive ratings. UBS initiated at Neutral with a $174 target on July 28, adding a cautious voice to the mix. The consensus mean target sits near $233, implying roughly 40% upside from current levels — but the gap between the Citigroup Neutral camp (target $172, barely above the current price) and the bull camp at RBC ($245) illustrates how wide the range of outcomes is. The bull case rests on Insulet's projected 20% revenue CAGR and the durability of the Omnipod franchise in the tubeless insulin delivery market. The bear case focuses on competitive pressure in the pump market, a possible slowdown in new patient starts, and the residual uncertainty from product recall events. EPS momentum factor scores rank in the 66th–69th percentile on both 30- and 90-day windows, suggesting estimates have been drifting modestly higher — a mild tailwind heading into the print.
One ownership note worth flagging: the insider register showed two board-level purchases in early June, with Independent Chairman Elizabeth Weatherman buying 3,450 shares at $144.20 ($497,000) and Independent Director Timothy Stonesifer adding 2,790 shares at $143.51 ($400,000). Those purchases came at prices meaningfully below the current level and represent the clearest insider signal in the recent record. T. Rowe Price reported a large increase of over 1.8 million shares as of June 30, the most notable institutional move in the top-holder data. Peers were mixed on the week: ATEC gained 11%, while SYK fell 3% and ABT slipped 1.7%, suggesting no sector-wide lift is carrying PODD into its report.
With earnings due after Wednesday's close, the key question is whether revenue guidance confirms the growth trajectory that bulls have priced in — options traders have made their bet, and the borrow market is not pushing back.
See the live data behind this article on ORTEX.
Open PODD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
